Frontotemporal Dementia Market, By Drug Class, By Disease Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

Frontotemporal Dementia Market size was valued at US$ 245.18 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Frontotemporal diseases are neurological conditions that cause nerve cell degeneration in the brain's frontal or temporal lobes. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, has a significant impact on behavior, language, movement, and personality, limiting people's ability to carry out daily tasks. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are neurological conditions that primarily affect the frontal and temporal lobes. This condition is defined by the progressive loss of nerve cells and the onset of dementia.

Frontotemporal Dementia Market- Market Dynamics

Rising Prevalence of Neurodegenerative Disorders Drives Market Growth

The growing prevalence of neurodegenerative disorders, particularly in the aging and genetically at-risk populations, is a major driver of the frontotemporal dementia (FTD) market. FTD is one of the most common causes of early-onset dementia, and more cases are being discovered around the world as awareness, diagnostics, and reporting improve. As life expectancy rises and neurological screening becomes more widely available, the demand for effective FTD treatments has increased. This trend is encouraging pharmaceutical and biotech companies to invest in new therapeutics, such as gene therapies and anti-tau drugs. In addition, healthcare systems are prioritizing early detection and intervention, which is driving market growth. The global burden of neurodegenerative diseases ensures that FTD remains a critical area of unmet medical need.

Frontotemporal Dementia Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to the segmentation of drug classes, antidepressants were expected to hold the largest market share in 2025.

According to segmentation of disease indications, frontotemporal dementia was the most common disease indication in 2025.

In 2025, North America ranked as the top revenue-generating region.

Frontotemporal Dementia Market- Segmentation Analysis:

The Global Frontotemporal Dementia Market is segmented on the basis of Drug Class, Disease Indication, Distribution Channel, and Region.

The market is separated into five groups according to the drug class: Cognitive Enhancers, Antidepressants, Antipsychotics, CNS Stimulants and Other Drug Classes. Antidepressants are expected to provide a lucrative opportunity during the forecast period. Antidepressant medications are primarily used to treat depressive disorders and other conditions such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain. Physicians frequently prescribe various types of antidepressants to improve patient health. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

The market is divided into three categories based on Disease Indication: Frontotemporal Dementia, Movement Disorders, and Primary Progressive Aphasia. Frontotemporal Dementia hold the largest market share in the Frontotemporal Dementia Market in 2025, and it is expected to grow further during the forecast period 2026-2030. Frontotemporal dementia is a collection of rare brain disorders that primarily affect the frontal and temporal lobes, resulting in changes in personality, language, and behavior. Despite frequently being misdiagnosed as Alzheimer's disease, frontotemporal dementia usually appears at a younger age, between 40 and 65.

Frontotemporal Dementia Market- Geographical Insights

North America dominates the market, owing to its advanced healthcare infrastructure, high healthcare expenditure, and extensive R&D activities. The United States, in particular, dominates the regional market due to its large elderly population and the presence of major pharmaceutical companies. The region's emphasis on early diagnosis and intervention, combined with extensive awareness campaigns, adds to its market leadership. The North American market is expected to grow at a steady CAGR over the forecast period.

The Asia Pacific region is expected to experience the most rapid growth during the forecast period. The region's large aging population, particularly in China, Japan, and India, drives up demand for dementia treatments. Increased healthcare investment and the adoption of advanced technologies help to drive market growth. The region's governments are actively promoting awareness campaigns and funding research initiatives to address the growing burden of dementia. The Asia Pacific market is expected to grow at a rapid CAGR, reflecting the region's emphasis on improving healthcare infrastructure and increasing access to dementia treatment.

Frontotemporal Dementia Market- Competitive Landscape:

The frontotemporal dementia (FTD) market is rapidly changing, with pharmaceutical giants and innovative biotech firms competing to develop effective treatments for this complex neurodegenerative condition. Leading companies, including Transposon Therapeutics, AstraZeneca plc, Alector Inc., Pfizer Inc., and Denali Therapeutics Inc., are conducting advanced research on disease-modifying treatments for tau protein accumulation and progranulin deficiencies. Orphan drug designations, growing collaborations between industry and academia, and increased investment in precision diagnostics are all driving the market forward.

Recent Developments:

In July 2024, The FDA has approved Alpha Cognition's oral therapy, ZUNVEYL, for the treatment of Alzheimer's disease in the US. This novel medication has a unique dual mechanism of action that improves cognitive function while providing better tolerability than existing treatments. ZUNVEYL is a promising advancement in Alzheimer's care that seeks to meet the unmet needs of patients and caregivers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Transposon Therapeutics
AstraZeneca plc
Alector Inc.
Pfizer Inc.
Denali Therapeutics Inc.
Johnson & Johnson Services Inc.
Prevail Therapeutics
Wave Life Sciences
GlaxoSmithKline plc
TauRx Pharmaceuticals Ltd.
Others

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Cognitive Enhancers
Antidepressants
Antipsychotics
CNS Stimulants
Other Drug Classes

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

Frontotemporal Dementia
Movement Disorders
Primary Progressive Aphasia

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5569

1. Frontotemporal Dementia Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Frontotemporal Dementia Market Snippet by Drug Class
- 2.1.2. Frontotemporal Dementia Market Snippet by Disease Indication
- 2.1.3. Frontotemporal Dementia Market Snippet by Distribution Channel
- 2.1.4. Frontotemporal Dementia Market Snippet by Country
- 2.1.5. Frontotemporal Dementia Market Snippet by Region
2.2. Competitive Insights

3. Frontotemporal Dementia Key Market Trends

3.1. Frontotemporal Dementia Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Frontotemporal Dementia Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Frontotemporal Dementia Market Opportunities
3.4. Frontotemporal Dementia Market Future Trends

4. Frontotemporal Dementia Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Frontotemporal Dementia Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Frontotemporal Dementia Market Landscape

6.1. Frontotemporal Dementia Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Frontotemporal Dementia Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 7.1.2. Cognitive Enhancers
- 7.1.3. Antidepressants
- 7.1.4. Antipsychotics
- 7.1.5. CNS Stimulants
- 7.1.6. Other Drug Classes

8. Frontotemporal Dementia Market - By Disease Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
- 8.1.2. Frontotemporal Dementia
- 8.1.3. Movement Disorders
- 8.1.4. Primary Progressive Aphasia

9. Frontotemporal Dementia Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 9.1.2. Hospital Pharmacies
- 9.1.3. Online Pharmacies
- 9.1.4. Retail Pharmacies

10. Frontotemporal Dementia Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Frontotemporal Dementia Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Frontotemporal Dementia Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Frontotemporal Dementia Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Frontotemporal Dementia Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Frontotemporal Dementia Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Frontotemporal Dementia Industry

11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Transposon Therapeutics
- 11.2.2. AstraZeneca plc
- 11.2.3. Alector Inc.
- 11.2.4. Pfizer Inc.
- 11.2.5. Denali Therapeutics Inc.
- 11.2.6. Johnson & Johnson Services Inc.
- 11.2.7. Prevail Therapeutics
- 11.2.8. Wave Life Sciences
- 11.2.9. GlaxoSmithKline plc
- 11.2.10. TauRx Pharmaceuticals Ltd.
- 11.2.11. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us